---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018705"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:25:41.249821+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma Q3 cash $16.2M; Phase 2 episodic migraine misses primary endpoint

## Summary
- Cash, equivalents and investments $16.2M as of Sep 30, 2023; expects to fund operations only into mid-December 2023.
- Phase 2 episodic migraine trial missed primary endpoint: mean MMD reduction 4.8 (150U) and 5.0 (195U) vs 4.2 placebo, not statistically significant.
- Secondary endpoints achieved statistical significance; company plans to advance to Phase 3 and request end-of-phase 2 meeting with FDA in 1H 2024.
- Chronic migraine Phase 2 enrollment on track to complete Q4 2023, topline data expected 2H 2024.
- Completed business combination and post-merger funding of ~$50M from new and existing investors.

## SEC filing metadata
- accession: 0001558370-23-018705
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/0001558370-23-018705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/aeon-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018705
- JSON: https://secwatch.observer/filing/0001558370-23-018705.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018705.txt

## Key facts
- Earnings Releases
  AEON Biopharma, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: AEON Biopharma, Inc. (the "Company") announced financial results for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000155837023018705/0001558370-23-018705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.